Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation
  • Ask Questions

Author: Tamas Sohajda

Cyclolab R&D Director
April 1, 2021 CD as API / CD derivatives

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement

Continue reading

March 18, 2021 CD as API / CD derivatives / Pharma applications

First results on cyclodextrins against dengue fever from CycloLab

In May, 2020, CycloLab announced a collaboration, where University of California, Berkeley, Excivion and CycloLab teamed-up to evaluate the antiviral

Continue reading

March 1, 2021 Drug delivery / Pharma applications

KAZIA LICENSES CANTRIXIL TO OASMIA

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, announced that it has entered into an exclusive worldwide license agreement with

Continue reading

February 19, 2021 Drug delivery / Pharma applications / Uncategorized

NIH funds study to evaluate remdesivir for COVID-19 in pregnancy

A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who

Continue reading

February 11, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and

Continue reading

February 1, 2021 Uncategorized

Happy 70th Birthday, Lajos!

CycloLab celebrates birthday of L. Szente (70), former CEO Lajos Szente has been contributing to the development of the global

Continue reading

January 28, 2021 Drug delivery / Pharma applications

Clinical trial for Postprandial Responses to ACD-encapsulated Hydroxytyrosol-enriched Bread

The amelioration of postprandial glucose and insulin responses to bread is of great importance since it may have significant beneficial

Continue reading

January 14, 2021 Drug delivery / Pharma applications

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,

Continue reading

January 11, 2021 CD as API / CD derivatives / Drug delivery / Pharma applications

Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs

Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development

Continue reading

January 8, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C

Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo

Continue reading

Posts navigation

1 2 3 … 12 Next Posts»

Recent Posts

  • Registration opened for virtual abridged meeting prior to International Cyclodextrin Symposium
  • Visible Light-Activatable Cyclodextrin-Conjugates for the Efficient Delivery of Nitric Oxide with Fluorescent Reporter and their Inclusion Complexes with Betaxolol
  • Evading Thermodynamic Constraints of Cyclodextrin-Drug Formulations
  • Cyclodextrins in Antiviral Therapeutics and Vaccines
  • FDA granted accelerated approval to umbralisib / HPBCD tablet

Tags

antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems Drugs FDA Food Gilead History HPBCD nanomedicine Nanoparticles nanotechnology Niemann Pick Disease Polymer remdesivir SBECD Special issue Synthesis Trappsol

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (9)
  • Analysis (14)
  • CD as API (106)
  • CD derivatives (140)
  • Cosmetics and toilettry (10)
  • Drug delivery (210)
  • E-ducation (41)
  • Environmental (44)
  • Events (102)
  • Food (60)
  • Gene delivery (6)
  • In Hungarian (4)
  • Non-pharma applications (103)
  • Other industrial use (36)
  • Pharma applications (373)
  • Supramolecular systems (7)
  • Uncategorized (23)

Top Posts

  • Registration opened for virtual abridged meeting prior to International Cyclodextrin Symposium
  • Visible Light-Activatable Cyclodextrin-Conjugates for the Efficient Delivery of Nitric Oxide with Fluorescent Reporter and their Inclusion Complexes with Betaxolol
  • Cyclodextrins in Antiviral Therapeutics and Vaccines
  • Evading Thermodynamic Constraints of Cyclodextrin-Drug Formulations
  • FDA granted accelerated approval to umbralisib / HPBCD tablet
  • The monograph of SBECD is official in the European Pharmacopeia
  • Nasal delivery with beta-cyclodextrin is approved; a short story of Baqsimi
  • How air fresheners work?
  • Reviews on cyclodextrin-metal-organic frameworks (CD-MOFs) in food applications
  • Host-guest chemistry for the treatment of leishmania

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 295 other subscribers